linjc16/ctgov huggingface dataset:
Xenon Inhalation for Treatment of Panic Disorder

Study Overview
=================
Brief Summary
-----------------
This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.

Official Title
-----------------
A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Panic Disorder

Conditions
-----------------
Panic Disorder

Intervention / Treatment
-----------------
* Drug: Xenon
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary diagnosis of panic disorder according to DSM-5. Male and female patients ≥18 years of age. Exclusion Criteria: History of schizophrenia, bipolar and other psychotic disorders. Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma, severe lung disease and/or baseline oxygen saturations <92% or any other respiratory conditions / diseases that may affect the respiratory function. Currently undergoing targeted empirically-driven psychotherapy for panic disorder or panic disorder-related symptoms. Currently undergoing exposure-based psychotherapy for any condition.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NBTX-001<br>Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume. | Drug: Xenon<br>* 30% xenon, 30% oxygen, and 40% nitrogen<br>|
| Placebo Comparator: Placebo<br>Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume. | Drug: Placebo<br>* 30% oxygen, and 70% nitrogen<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PDSS | Panic Disorder Severity Scale | Baseline to Week 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PHQ-9 | Patient Health Questionnaire-9 | Baseline to Week 6 |
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Study Overview
=================
Brief Summary
-----------------
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

Detailed Description
-----------------
A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.

Official Title
-----------------
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Saquinavir
* Drug: Lamivudine
* Drug: Zidovudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HIV antibody positive. CD4 count >= 150 and <= 500 cells/mm3. Exclusion Criteria Prior Medication: Excluded: Prior antiretroviral therapy. Prior protease inhibitor therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Saquinavir|nan|
|Drug: Lamivudine|nan|
|Drug: Zidovudine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Therapy, Combination, Zidovudine, HIV Protease Inhibitors, Lamivudine, Saquinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents
Kinesio Taping and Manual Therapy Efficacity on Lumbar Pain During Pregnancy

Study Overview
=================
Brief Summary
-----------------
Pregnant women often suffer from lumbar pain , specially during the last semester . Usually physiotherapy and manual therapy on TRIGGER point help them . But there is also another type of support , the Kinesio-Taping using the pose of a strip which aims to mobilize the muscle without any restriction. The purpose is to reduce the pain with the combo therapy (TRIGGER point plus Kinesi Taping)

Official Title
-----------------
Kinesio Taping and Manual Therapy Efficacity on Lumbar Pain During Pregnancy

Conditions
-----------------
Manual Therapy

Intervention / Treatment
-----------------
* Procedure: TRIGGER
* Procedure: TRIGGER+CURETAPE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 french speaking single pregnancy lumbar pain EIFEL score>6 medical insurance Exclusion Criteria: twins pregnancy rachial arthrodesis Probable Acrylique allergy Psoriasis or other cutaneous problems circulatory disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: TRIGGER<br> | Procedure: TRIGGER<br>* only TRIGGER point will be included for the manual therapy<br>|
| Experimental: TRIGGER+CURETAPE<br> | Procedure: TRIGGER+CURETAPE<br>* TRIGGER point will be included for the manual therapy with kinesio-taping<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| French version of Roland-Morris questionnaire in chronic low back pain patients EIFEL Échelle d'Incapacité Fonctionnelle pour l'Évaluation des Lombalgies questionnaire) score | EIFEL questionnaire is filled by patient between week 30 of pregnancy to week 38, scale range from 0 to 24, | change from week 30 to week 38 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain scale | Pain scale is filled by patient between week 30 of pregnancay to week 30, scale range from 0 to 10 | change from week 30 to week 38 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lumbar pain; pregnancy;
The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations

Study Overview
=================
Brief Summary
-----------------
The intention of this trial is to assess the safety and efficacy of Drug Eluting Balloon (DEB) application (SeQuent Please) to the side branch in percutaneous coronary intervention (PCI) of Medina 0,0,1 coronary bifurcation lesions. Patients will be randomized to treatment with Plain Old Balloon Angioplasty (POBA)or treatment with DEB.

Official Title
-----------------
The Paclitaxel-Eluting PTCA-Balloon Catheter for the Treatment of Coronary Bifurcations

Conditions
-----------------
Angioplasty

Intervention / Treatment
-----------------
* Procedure: Percutaneous coronary intervention (PCI)
* Procedure: PCI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (main): De-novo Medina type 0,0,1 bifurcational native coronary artery lesion (reference diameter:>2.0 mm <3.5 mm, length of stenosis: ≤ 10 mm), the diameter of the side branch shall be smaller or equal to the diameter of the distal end vessel Exclusion Criteria (main): Reference side branch diameter > 3.5 mm Evidence of extensive thrombosis within target vessel Patients with another coronary stent implanted previously into the target branch or bifurcation ≤ 15 mm distant to the current lesion, drug eluting stents less than 9 months and bare metal stents or stents with passive coatings less than 3 months before the PEPCAD- BIF

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Drug Eluting Balloon<br> | Procedure: Percutaneous coronary intervention (PCI)<br>* balloon angioplasty<br>|
| Active Comparator: Plain Old Balloon Angioplasty (POBA)<br> | Procedure: PCI<br>* balloon angioplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-segment late lumen loss in the side branch at 9 months |  | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Angioplasty Balloon
Zenith Low Profile AAA Endovascular Graft (ZLP) Clinical Study

Study Overview
=================
Brief Summary
-----------------
A prospective study conducted in Japan to collect confirmatory peri-operative and 30-day information on use of the Zenith LP AAA Graft.

Official Title
-----------------
ZLP Clinical Study

Conditions
-----------------
Abdominal Aortic Aneurysm, Aorto-iliac Aneurysm, Iliac Aneurysm

Intervention / Treatment
-----------------
* Device: ZLP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Abdominal aortic, aorto-iliac, and iliac aneurysms of appropriate size Vessels suitable for endovascular access and aneurysm repair Exclusion Criteria: Less than 20 years of age Inability or refusal to give informed consent Disease considerations that would compromise patient safety or study outcomes Unsuitable arterial anatomy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Endovascular Repair | Device: ZLP<br>* ZLP Graft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite rate of adverse clinical/device events |  | During (day 1) and after implantation through 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aortic aneurysm, iliac aneurysm, endovascular procedures
National French Survey on Psychological Distress at Work of Anesthesia and Intensive Care Residents

Study Overview
=================
Brief Summary
-----------------
Psychological distress is a significant problem for healthcare professionals and students in training. The investigator question the prevalence of this problem in French residents in anaesthesia and intensive care training.

Detailed Description
-----------------
The investigator performed an observational study on the national population of anaesthesia residents. A questionnaire was sent to all residents composed with validated questionnaires analyzing psychological distress (Hospital Anxiety and Depression Scale (HADS), Copenhagen Burnout Inventory (CBI), Perceived Stress Scale (PSS), Karasek's questionnaire; work-related questions (work hours per week, night shift per month, application of safety rest after night shift, average time to start and end work, break time and time for food per day; two semi-open work-related questions (main stressor during internship, professional orientation); a free verbatim.

Official Title
-----------------
National French Survey on Psychological Distress at Work of Anesthesia and Intensive Care Residents

Conditions
-----------------
Burnout, Professional, Intensive Care, Anesthesia, Depression, Anxiety, Stress, Psychological, Fatigue, Work Load

Intervention / Treatment
-----------------
* Behavioral: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: resident of intensive care or anesthesia, french Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital Anxiety and Depression Scale (HADS) | Investigation of the anxiety and depression with 14 questions, the cut-off score is more than 11 for anxiety or depression | baseline | 
| Copenhagen Burnout Inventory (CBI) | Investigation of the burnout on 3 axes: personal, professional and relational with 19 questions, the cut-off score is 50 to identify a burnout | baseline | 
| Karacek's questionnaire | Investigation of the stress at work | baseline | 
| Perceived Stress Scale (PSS) | Investigation of the stress with 10 questions | baseline |
Transversus Abdominis Plane Block For Renal Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy of a local anaesthetic injection in the plane between the abdominal muscles in reducing the amount of pain relief required after surgery.

Detailed Description
-----------------
The aim of this study is to evaluate the efficacy of transversus abdominis plane block in reducing the morphine requirements after renal transplantation.

Official Title
-----------------
Transversus Abdominis Plane Block For Renal Transplant Recipients: A Randomized Controlled Double-blinded Study

Conditions
-----------------
Disorder Related to Renal Transplantation, Pain

Intervention / Treatment
-----------------
* Procedure: TAP block
* Procedure: TAP block with placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: renal transplant recipients 18 to 75 years Exclusion Criteria: allergy to local anaesthetics chronic pain refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Transversus abdominis plane (TAP) Group<br>Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia | Procedure: TAP block<br>* TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group<br>|
| Placebo Comparator: Control Group<br>Patients will receive a TAP block using a placebo after induction of anaesthesia | Procedure: TAP block with placebo<br>* TAP block using a placebo after induction of anaesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morphine consumption in first 24 hours after renal transplantation |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transversus abdominis plane block, relief
Assessment of Limb Perfusion During Junctional Tourniquet

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to use contrast enhanced ultrasound to determine the degree to which flow is reduced during application of a junctional tourniquet (JT). Contrast enhanced ultrasound is performed to quantify thigh and calf perfusion at baseline and during application of the JT

Official Title
-----------------
Assessment of Limb Perfusion During Junctional Tourniquet

Conditions
-----------------
Bleeding

Intervention / Treatment
-----------------
* Device: Application of a Junctional Tourniquet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subject Age 19-50 Exclusion Criteria: Peripheral artery disease Known heart failure Right to left shunt Pregnancy Presence of femoral artery aneurysm

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Normal subjects<br>Normal subjects, all of whom undergo brief application of junctional tourniquet | Device: Application of a Junctional Tourniquet<br>* All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle Perfusion | Contrast ultrasound perfusion imaging will be performed at baseline and 1 min after application of the JT. | baseline and 1 min post occlusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tourniquet, Muscle perfusion, Contrast ultrasound
Clinical Evaluation of the Levita Robotic Platform

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and feasibility of the Levita Robotic Platform (LRP) used with the Levita Magnetic Surgical System (MSS)

Detailed Description
-----------------
Prospective, multi-center, single-arm, open label study designed to assess the safety and feasibility of the use of the Levita Robotic Platform with the Levita Magnetic Surgical System in laparoscopic procedures.

Official Title
-----------------
Clinical Evaluation of the Levita Robotic Platform

Conditions
-----------------
Bariatric Surgery Candidate, Cholelithiases, Other Disease

Intervention / Treatment
-----------------
* Device: Levita Robotic Platform


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Subject is at least 18 years of age Subject is scheduled to undergo elective laparoscopic procedure Subject signs a written Informed Consent Form (ICF) to participate in the study prior to any study required procedures Exclusion Criteria: • Subjects with pacemakers, defibrillators, or other electromedical implants Subjects with ferromagnetic implants Subjects with significant comorbidities: cardiovascular, neuromuscular, chronic obstructive pulmonary disease, and urological disease (renal failure) Subjects with a clinical history of impaired coagulation confirmed by abnormal blood tests Subject has an anatomical abnormality or disease of intended target tissue noted after initiation of index procedure that would prevent device use Subject is pregnant or wishes to become pregnant during the length of study participation Subject is not likely to comply with the follow-up evaluation schedule Subject is participating in a clinical trial of another investigational drug or device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Levita Robotic Platform<br> | Device: Levita Robotic Platform<br>* Levita Robotic Platform<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events- Safety | Adverse events related to the device | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate that the Levita Robotic Platform is able to engage, move, and decouple with the Magnetic Surgical System as controlled by the surgeon | Ratio of successful attempts vs unsuccessful attempts | Surgery time | 
| Conversion rate to open surgery | Ratio of conversion from laparoscopic to open surgery due to inability of the robotic system to provide adequate visualization | Surgery time |